Nasdaq grants revelation biosciences inc. continued listing

San diego--(business wire)---- $revb #gemini--revelation biosciences, inc. (nasdaq: revb) (the “company” or “revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the nasdaq hearings panel issued a decision letter granting revelation's request to continue its listing on the nasdaq stock market, subject to its stock trading at or above $1.00 for at least ten consecutive trading days by february 14, 2025.
NDAQ Ratings Summary
NDAQ Quant Ranking